ClinicalTrials.gg
CompletedNCT07650331Updated Jun 16, 2026

Inter- and Intra-Rater Reliability of a Wearable Inertial Sensor for Spatiotemporal Gait Assessment in Stroke Survivors

An observational study in Stroke, sponsored by Neuron, Spain. Completed at 1 site in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Neuron, Spain · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
24
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 323 studies in Stroke with a site in Spain — 73 open to participants now, 91 under way, 6 of them phase 3. Stroke · Spain.

Enrollment
75th of 77
24 · median 250
Started
2025
with 28 others
Observational
77 of 323
16 open now
Registered
308th of 323
by date

Among the 323 studies in Stroke with a site in Spain, this one is the 75th largest by enrollment of the 77 observational ones that give a count, is one of 29 that started in 2025, is one of 77 observational ones, and was the 308th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

73 of the 323 studies in Stroke with a site in Spain are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 323 studies in Stroke with a site in Spain, or all of them as a file.
02

Study summary

Background and Objective:

Stroke frequently impairs gait functionality, leading to significant limitations in functional independence and quality of life. Objective gait analysis is essential for evaluating clinical status and rehabilitation progress. While laboratory-bound, non-wearable systems are considered the gold standard, their high cost, complex infrastructure, and requirement for specialized personnel limit their routine implementation in daily clinical practice. Portable inertial measurement units have emerged as a practical, low-cost alternative for motion analysis outside traditional laboratory settings. However, evidence regarding specific commercial devices in pathological populations remains limited. This study aims to evaluate the inter-rater and intra-rater reliability of the commercially available Baiobit® lumbar-mounted inertial sensor for measuring spatiotemporal gait parameters in stroke survivors.

Methodology:

A prospective, single-group, repeated-measures design was conducted at a specialized neurorehabilitation clinic (Neuron Clinic, Madrid). A convenience sample of 22 adults diagnosed with subacute or chronic stroke who were able to ambulate independently was included. Gait assessments were performed by two trained evaluators across two separate sessions spaced 24 to 48 hours apart. During each session, the Baiobit® sensor was secured to the participants' sacral region (S1-S2) using an adjustable belt. Participants performed three 10-meter walking trials at their comfortable, self-selected pace for each evaluator. Reliability was quantified using Intraclass Correlation Coefficients (ICC), Standard Error of Measurement (SEM), and Minimal Detectable Change (MDC).

Expected Outcomes:

It is hypothesized that the Baiobit® inertial sensor will demonstrate adequate relative and absolute inter- and intra-rater reliability across spatiotemporal gait parameters, supporting its viability as an objective monitoring tool in routine stroke rehabilitation clinical settings.

Read the detailed description

Introduction and Rationale Stroke survivors commonly experience sensorimotor sequelae that heavily compromise walking patterns, typically presenting reduced speed, lower cadence, shortened step length, and prolonged double-support time. Objective quantification of these spatiotemporal parameters is critical to direct therapeutic goals and evaluate rehabilitation outcomes. To overcome the financial and logistical barriers of traditional motion laboratories, wearable inertial measurement units (IMUs) are increasingly proposed due to their portability and ease of use. However, substantial heterogeneity in sensor configurations and algorithms necessitates population-specific metric validation. The Baiobit® system is an emerging commercial IMU that integrates a triaxial accelerometer, gyroscope, and magnetometer operating at 200 Hz to estimate gait metrics via internal event-detection algorithms. To date, no study has established its measurement consistency and repeatability specifically for stroke survivors.

Study Population and Eligibility Participants were recruited via convenience sampling from the outpatient database at Neuron Clinics in Madrid, Spain. To ensure safety and protocol compliance, strict eligibility criteria were applied: Inclusion Criteria: (1) Adults aged 18 to 85 years; (2) a confirmed diagnosis of ischemic or hemorrhagic stroke with a time since onset $> 1$ month; (3) ability to ambulate independently (Functional Ambulation Categories FAC > 4) regardless of foot-up orthosis use; (4) capacity to walk 10 meters without stopping and repeat the trial six times across the protocol; and (5) cognitive ability to understand instructions and provide written informed consent. Exclusion Criteria: (1) Medical instability or acute conditions comprising gait safety; (2) concomitant neurological conditions other than stroke; (3) severe musculoskeletal disorders interfering with locomotion; (4) visual or auditory deficits severely impairing balance; (5) recent use of medications affecting gait or postural control (e.g., benzodiazepines, antipsychotics, or opioids); and (6) pregnancy. Randomization and Blinding Protocols To control for sequence and order biases, a 1:1 block randomization scheme was generated using a digital tool (randomizer.org) to determine the evaluation sequence between the two raters. Blinding was coordinated by a third independent researcher who managed the logistical workflows, handled independent password-protected software accounts for each rater, and exported raw data to a masked master database. This design strictly prevented the two evaluators from assessing participants simultaneously or accessing each other's data records.

Experimental Procedures The data collection protocol spanned two distinct evaluation sessions scheduled 24 to 48 hours apart to minimize clinical fluctuations while preventing recall bias. Familiarization: In the first session, after formal enrollment and collection of sociodemographic data, participants were familiarized with the environment, and the 10-meter walkway was demonstrated. Sensor Placement: The Baiobit® sensor was securely mounted on the sacral region corresponding to the S1-S2 vertebrae using the manufacturer's adjustable elastic belt. Data Acquisition: Participants performed three 10-meter walking trials at their comfortable, self-selected pace per evaluator. The first assigned evaluator positioned the sensor, acquired the recordings, and completely removed the device. Rest Period: A mandatory 10-minute seated rest period was enforced between evaluators to mitigate fatigue effects. Replication: The second evaluator repeated the exact preparation, placement, and trial recording steps. This identical sequence was replicated during the second session under unvaried environmental conditions.

Outcome Measures and Biomechanical Variables Spatiotemporal gait variables were recorded bilaterally by the sensor software algorithms, capturing: gait speed (m/s), cadence (steps/min), step and stride lengths (m), percentages (%) of stance and swing phases, single-leg and double-leg stance durations, and propulsion metrics. Statistical Analysis PlanData normality was verified using the Shapiro-Wilk test. Continuous demographics are reported as mean and standard deviation (SD). Relative reliability was analyzed using Intraclass Correlation Coefficients (ICCs) with 95% confidence intervals (95% CIs). A two-way mixed-effects consistency model was selected for intra-rater reliability, and a two-way random-effects absolute agreement model was utilized for inter-rater reliability. Absolute reliability and precision were quantified calculating the Standard Error of Measurement. The Minimal Detectable Change was calculated to define the true clinical change threshold. Bland-Altman plotting was performed to identify systematic biases and calculate the limits of agreement (LoA).

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Stroke
  • Gait rehabilitation
  • Inertial measurement units
  • Validation
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of a convenience sample of adult stroke survivors receiving outpatient physical therapy and neurorehabilitation care. Participants include individuals with a confirmed diagnosis of either ischemic or hemorrhagic stroke, in both subacute and chronic stages (time since onset greater than one month), who retain the functional capacity to ambulate independently on overground surfaces without physical assistance. All participants are recruited from the outpatient facilities of a specialized neurorehabilitation center (Neuron Clinics) located in Madrid, Spain.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults aged 18-85 years
  • confirmed diagnosis of stroke
  • ability to ambulate (FAC > 4), regardless of foot-up use
  • Capacity to walk 10m without stopping and repeat the trials 6 times across the session
  • Cognitive ability to understand the study instruction and provide written

Exclusion criteria

Exclusion Criteria:

  • clinical instability or acute medical conditions that compromise gait safety
  • concomitant neurological conditions other than stroke
  • severe musculoskeletal disorders that interfere with gait analysis
  • balance or coordination impairments secondary to visual or auditory deficits
  • recent use of substances or medications that impair bait, balance, or postural control
  • pregnancy
  • cognitive or behavioral impairments that prevent the proper performance of the test
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
24 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants

    All the participants included

06

What researchers measure

Primary outcomes

  1. Intra-rater reliability of spatiotemporal gait parameters

    Relative and absolute consistency of spatiotemporal gait metrics derived from repeated measurements taken by the same evaluator

    Time frame: Up to 48 hours

Secondary outcomes

  1. Inter-rater reliability of spatiotemporal gait parameters

    Relative and absolute consistency of spatiotemporal gait metrics recorder simultaneously by two independent, trained evaluators

    Time frame: Day 1 and day 2

07

Study locations

1 site
  • Neuron Madrid Río
    Madrid, Madrid 28045, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Database used for the analyses will be published in zenodo website

Supporting information: Analytic code

Time frame: Data will be uploaded once analyzed

Access criteria: Anybody

Data sharing details ↗ · zenodo.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Apr 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 16, 2026
StartActual
Oct 10, 2025
Primary completionActual
Apr 20, 2026
CompletionActual
May 14, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07650331
Lead sponsor
Neuron, Spain
Responsible party
Alejandro Herrera Rojas (Physical therapist, Neuron, Spain) — Principal investigator
First posted
Jun 16, 2026
Start date
Oct 10, 2025
Primary completion
Apr 20, 2026
Completion
May 14, 2026
Last update
Jun 16, 2026

Study contacts

Alejandro Herrera Rojas, Physical Therapist
principal investigator · Neuron, Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion